{"analyses":[{"ciLowerLimit":"59.2","ciNumSides":"ONE_SIDED","ciPctValue":"90","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","pValueComment":"One sided log rank test","paramType":"PFS at 18 Months","paramValue":"70.8","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.2","upperLimit":"100","value":"70.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Disease Free Survival (DFS) is defined as the time from the date of Peripheral Blood Stem Cell Transplant (PBSCT) to first documentation of relapse or death due to any cause, whichever comes first.","dispersionType":"90% Confidence Interval","groups":[{"description":"All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)\n\nFludarabine: Fludarabine 30mg/m\\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\\^2\n\nMelphalan: Melphalan 70 mg/m\\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.\n\nTotal Body Irradiation: Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)","id":"OG000","title":"Conditioning Regimen + Transplant"}],"paramType":"NUMBER","populationDescription":"Evaluable Participants","reportingStatus":"POSTED","timeFrame":"Up to 18 months post-transplant","title":"Disease Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}